Country . | Year of publication . | Databases . | Specialty . | Authors/society . | Classification . | Antibiotherapy . | Dosage . | Duration . |
---|---|---|---|---|---|---|---|---|
GP coauthors (yes/no) . | ||||||||
Argentina (56) | 2018 | MEDLINE | Pluriprofessional GP (No) | Corina Nemirovsky et al. | Cystitis | Nitrofurantoin | 100 mg QID | 7 days |
Cefalexin | 500 mg TID | |||||||
Alternative | ||||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Argentine Society of Infectious Diseases (ASID) | Pyelonephritis | Ceftriaxon | 1 g OD | 10 days | ||||
Cefixim | 400 mg OD | |||||||
Ciprofloxacin | 500 mg BD | 7 days | ||||||
Acute bacterial prostatitis | Ceftriaxon | 1–2 g OD | 2–4 weeks | |||||
Asia (49) | 2021 | MEDLINE | Urology GP (No) | Matsumoto et al. | Acute bacterial prostatitis | Probabilist | ||
Fluoroquinolon | N/A | 10–28 days | ||||||
Asian Association of Urinary Tract Infection and Sexually Transmitted Infection (AAUS) | After antibiogram: first choice | |||||||
Fluoroquinolon | N/A | 10–28 days | ||||||
After antibiogram: second choice if R-FQ | ||||||||
3rd CEP | N/A | 14–28 days | ||||||
Co-amoxiclav | N/A | |||||||
Cotrimoxazole | N/A | |||||||
Brazil (57) | 2005 | MEDLINE | Pluriprofessional GP (No) | Hélio Vasconcellos Lopes et al. | Cystitis | N/A | N/A | N/A |
Brazilian Society of Infectiology (SBI); Brazilian Society of Urology (SBU) | Pyelonephritis | N/A | N/A | N/A | ||||
Canada (Quebec) (60) | 2017 | National Institute for Health Excellence (INESS) | Pluriprofessional GP (Yes) | Fatiha Karam et al. | Complicated or at risk urinary tract infection | First choice | ||
Ciprofoloxacin | 500 mg BD | 10–14 days | ||||||
National Institute for Health Excellence (INESS) | Ciprofloxacin XL | 1000 mg OD | ||||||
Levofloxacin | 500 mg OD | |||||||
after obtaining the antibiogram only | ||||||||
Cotrimoxazole | 160/800 mg BD | Cystitis: 7–10 days | ||||||
Pyelonephritis: 10–14 days | ||||||||
Co-amoxiclav | 875–125 mg BD | 10–14 days | ||||||
Cefadroxil | 500 mg BID | |||||||
Cefalexin | 500 mg QID | |||||||
Cefixim | 400 mg OD | |||||||
Croatia (30,31) | 2004 | MEDLINE | Pluriprofessional GP (Yes) | Visnja Skerk et al. | Cystitis | 2nd CEP | N/A | 7 days |
Co-amoxiclav | ||||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Ciprofloxacin | |||||||
Nitrofurantoin | ||||||||
Cotrimoxazole | ||||||||
Pyelonephritis | N/A | N/A | N/A | |||||
Prostatitis | 2nd CEP | N/A | N/A | |||||
3rd CEP | N/A | N/A | ||||||
Co-amoxiclav | N/A | 4–6 weeks | ||||||
2004, updated in 2009 | MEDLINE | Pluriprofessional GP (Yes) | Visnja skerk et al. | Acute UTI and systemic symptoms | First choice | |||
Ciprofloxacin | 500 mg BD | 2 weeks | ||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Alternative choice | |||||||
Co-amoxiclav | 1 g BD | 2 weeks | ||||||
Cefuroxim-axétil | 500 mg BD | |||||||
Ceftibuten | 400 mg OD | |||||||
Cefixim | 400 mg OD | |||||||
Denmark (32) | 2020 | Common public health portal (Sundhed.dk) | Pluriprofessional GP (Yes) | Ulrich Stab Jensen et al. | Complicated urinary tract infection | Pivmecillinam | 400 mg TID | 5 days |
Nitrofurantoin | 100 mg BD | 5 days | ||||||
Sundhed | Pyelonephritis | Pivmecillinam | 400 mg TID | 10–14 days | ||||
Nitrofurantoin | 500 mg BD | 7 days | ||||||
Ethiopia (50) | 2010 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Eyasu Makonnen et al. | Male urinary tract infection | First choice | ||
Cotrimoxazole | 800/160 mg BD | 10–14 days | ||||||
Ministry of Health | Second choice | |||||||
Norfloxacin | 400 mg BD | 10–14 days | ||||||
Amoxicillin | 250–500 mg TID | |||||||
Europe (33,62) | 2001 | MEDLINE | Urology GP (No) | Kurt G. Naber et al. | Prostatitis | Fluoroquinolones | N/A | 14 days |
European Association of Urology (EAU) | 2nd CEP | N/A | ||||||
2001, updated in 2021 | Uroweb | Urology GP (No) | G. Bonkat et al. | Cystitis | Cotrimoxazole | 800/160 mg BD | 7 days | |
Restricted to men, fluoroquinolones can also be prescribed in accordance with local susceptibility testing | ||||||||
European Association of Urology (EAU) | Complicated UTIs | Ciprofloxacin | 500–750 mg | 14 days | ||||
3rd CEP | N/A | |||||||
Acute Bacterial Prostatitis | Same lines of complicated UTIs | |||||||
Finland (34,61) | 2011 | MEDLINE | Pluriprofessional GP (Yes) | R. De Rosa et al. | Cystitis | Trimethoprim | 160 mg BD or 300 m OD | 7–14 days |
Fluoroquinolones | N/A | |||||||
Finnish Medical Society Duodecim (DUODECIM) | Pyelonephritis | Fluoroquinolones | N/A | 14 days | ||||
Prostatitis | Fluoroquinolones | N/A | 4 weeks | |||||
2011, updated in 2021 | Finnish Medical Society DUODECIM* | Pluriprofessional GP (Yes) | Finnish Medical Society Duodecim (DUODECIM) | Cystitis | Trimethoprim | 160 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
Nitrofurantoin | 75 mg BD | |||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Pyelonephritis | Ciprofloxacin | 500 mg BD | 5–7 days | |||||
Levofloxacin | 250–500 mg OD | |||||||
Cefuroxim | 750–1500 mg TID | 10–14 days | ||||||
Cotrimoxazole | 160/800 mg x 2/d | 10 days | ||||||
Acute bacterial prostatitis | Cotrimoxazole | 160/800 mg OD | 4–6 weeks | |||||
Ciprofloxacin | N/A | |||||||
Norfloxacin | N/A | |||||||
France (22,63) | 2008 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Prostatitis | Ciprofloxacin | 500–750 mg BD | 15–21 days |
Levofloxacin | 500 mg OD | |||||||
French Infectious Diseases Society (SPILF) | Ofloxacin | 200 mg × 2–3/d | ||||||
2008, updated in 2018 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Male urinary tract infection | After obtaining the antibiogram only | |||
Pauci symptomatic (no fever) | First choice | |||||||
French Infectious Diseases Society (SPILF) | Ciprofloxacin | 500 mg BD | 14 days | |||||
Levofloxacin | 500 mg OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Second choice | ||||||||
Cotrimoxazole | 800/160 mg BD | 14 days | ||||||
Third choice | ||||||||
Cefotaxim | 1 g TID | 14 days | ||||||
Ceftriaxon | 1 g OD | |||||||
Male urinary tract infection | Same lines as male UTI pauci symptomatic in probabilistic | |||||||
symptomatic (fever) | ||||||||
Germany (35,36) | 2011, updated in 2017 | MEDLINE | Pluriprofessional GP (Yes) | F.M.E. Wagenlehner et al. (2011) | Cystitis (Healthy young men) | First choice | ||
Kranz et al. (2017) | Ciprofloxacin RT | 500 mg OD | 3 days | |||||
Ciprofloxacin | 250 mg BD | |||||||
German Association of Scientific Medical Societies (AWMF) | Levofloxacin | 250 mg OD | ||||||
Norfloxacin | 400 mg BD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cefpodoxim-proxetil | 100 mg BD | |||||||
According to local resistance rate | ||||||||
Cotrimoxazole | 160/800mg BD | 3 days | ||||||
Trimethoprim | 200 BD | 5 days | ||||||
Pyelonephritis | First choice | |||||||
Ciprofloxacin | 1000 mg OD | 7–10 days | ||||||
500–750 mg BD | ||||||||
Levofloxacin | 500 mg OD | |||||||
750 mg OD | 5 jours | |||||||
Second choice | ||||||||
Cefpodoxim-proxetil | 200 mg BD | 10 jours | ||||||
Ceftibuten | 400 mg OD | |||||||
After antibiogram | ||||||||
Cotrimoxazole | 160/800 mg BID | 14 jours | ||||||
Co-amoxiclav | 875/125 mg BID | |||||||
500/125 mg BID | ||||||||
Japan (46,83,84) | 2011, updated in 2015 and 2016 | MEDLINE | Pluriprofessional GP (No) | Yasuda et al. (2011/2016) | Complicated cystitis | First choice | ||
Yamamoto et al. (2015) | Levofloxacin | 500 mg OD | 7–14 days | |||||
Ciprofloxacin | 200 mg BID TID | |||||||
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy (JAID/JSC) | Temafloxacin | 150 mg BID | ||||||
Sitafloxacin | 100 mg OD | |||||||
Co-amoxiclav | 250 mg TID | |||||||
Sultamicillin | 375 mg TID | |||||||
Alternative | ||||||||
Cefdinir | 100 mg TID | 7–14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 mg TID | |||||||
Complicated pyelonephritis | First choice | |||||||
Levofloxacin | 500 mg OD | 7–14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Cefditoren pivoxil | 200 mg TID | 14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 TID | |||||||
Acute bacterial prostatitis | First choice | |||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Sultamicillin | 375 mg TID | 14–28 days | ||||||
Cotrimoxazole | 160/800 mg BID | 14 days | ||||||
Norway (37,38) | 2019 | Antibiotics Centre for Primary Medicine | General Practice GP (Yes) | Anders Baerheim et al. | Complicated cystitis (no fever) | Nitrofurantoin | 50 mg TID | 5–7 days |
Pivmecillinam | 200–400 mg TID | |||||||
Primary Care Antibiotic Centre | Trimethoprim | 160 mg BD | ||||||
Complicated cystitis (fever) | Cotrimoxazole | 160/800 mg × 2 BD | 5–7 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Sigurd Haugan Danielsen et al. | Prostatitis | First choice | ||||||
Cotrimoxazole | 160/800 mg × 2 BD | 14 days | ||||||
Primary Care Antibiotic Centre | Second choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
2021 | General Directorate of Health | Pluriprofessional GP (Yes) | Bjorn Waagsbo et al. | Complicated cystitis | Pivmecillinam | 200 mg TID | 7 days | |
Nitrofurantoin | 50 mg TID | |||||||
Norwegian Directorate of Health | Trimethoprim | 160 mg BD | ||||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Prostatitis | Ciprofloxacin | 500 mg BD | 14 days | |||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Cefotaxim | 1 g TID | |||||||
If atypical germs | ||||||||
Azithromycin | 1 g OD | 14 days | ||||||
Doxycycline | 100 mg OD | |||||||
Netherlands (39,40) | 2006 | MEDLINE | General Practice GP (Yes) | B. van Pinxteren et al. | Complicated urinary tract infection | First line | ||
Nitrofurantoin | N/A | 7 days | ||||||
College of General Practitioners (NHG) | Second line | |||||||
Trimethoprim | N/A | 7 days | ||||||
2013 | Dutch Working Party on Antibiotic Policy (SWAB) | Pluriprofessional GP (Yes) | Geerlings et al. | Cystitis (young men) | Cf. recommendations of College of General Practitioners (NHG) | |||
Urinary tract infection with systemic symptoms (pyelonephritis and acute prostatitis) | Ciprofloxacin | 500 mg BID | 14 days | |||||
Dutch Working Party on Antibiotic Policy (SWAB) | Cotrimoxazole | N/A | ||||||
2020 | College of General Practitioners (NHG) | Pluriprofessional GP (Yes) | M. Bouma et al. | Cystitis | First choice | |||
Nitrofurantoin | 100 mg BID | 7 days | ||||||
College of General Practitioners (NHG) | 50 mg QID | |||||||
Second choice | ||||||||
Trimethoprim | 300 mg OD | 7 days | ||||||
UTI with signs of tissue invasion | First choice | |||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Second choice | ||||||||
Co-amoxiclav | 500/125 mg TID | 14 days | ||||||
Third choice | ||||||||
Cotrimoxazole | 160/800 BID | 14 days | ||||||
Scotland (59) | 2012 | Scottish Intercollegiate | Pluriprofessional GP (No | Scottish Intercollegiate | Lower urinary tract infection | Trimethoprim | N/A | 7 days |
Guidelines Network (SIGN) | ) | Guidelines Network (SIGN) | Nitrofurantoin | N/A | ||||
Prostatitis | Quinolone | N/A | 4 weeks | |||||
South Africa (51) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | T.D. Mseleku et al. | Acute bacterial prostatitis | Men < 35 years old | ||
Ciprofloxacin | 500 mg | Single dose | ||||||
Ministry of Health | Followed by | |||||||
Doxycyclin | 100 mg BD | 7 days | ||||||
Men > 35 years old | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
South Korea (47) | 2018 | MEDLINE | Pluriprofessional GP (No) | Cheol-In Kang et al. | Pyelonephritis | Ciprofloxacin | 500 mg BD | 7 days |
Levofloxacin | 750 mg OD | 5 days | ||||||
Korean Society of Infectious Diseases (KSID) | Ceftibuten | 400 mg OD | 10 days | |||||
Cefpodoxim | 200 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
Prostatitis | 3rd CEP | N/A | 2–4 weeks | |||||
Co-amoxiclav | ||||||||
Spain (41) | 2017 | MEDLINE | Pluriprofessional GP (No) | Marina de Cueto et al. | Uncomplicated cystitis | N/A | N/A | 7 days minimum |
Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) | ||||||||
Sweden (42) | Public Health Agency | Pluriprofessional GP (Yes | Tegnell et al. | Cystitis | Ciprofloxacin | N/A | 2 weeks | |
) | Nitrofurantoin | 7 days | ||||||
Public Health Agency | Pivmecillinam | |||||||
Pyelonephritis | Ciprofloxacin | N/A | 2 weeks | |||||
Trimethoprim | N/A | |||||||
Switzerland (43) | 2014 | Swiss Society of Infectious Diseases | Pluriprofessional GP (No) | Barbara Hasse et al. | Cystitis | Fluoroquinolon | N/A | 7–10 days |
Cotrimoxazole | 7–10 days | |||||||
Swiss Society of Infectious Diseases | Pyelonephritis | Fluoroquinolone | N/A | 14 days | ||||
Cotrimoxazole | ||||||||
Prostatitis | Fluoroquinolon | N/A | 14–21 days | |||||
Cotrimoxazole | ||||||||
Taiwan (48) | 2000 | MEDLINE | Infectiology GP (No) | Feng-Yee Chang et al. | Prostatitis | Amoxicillin | N/A | N/A |
3rd CEP | ||||||||
Infectious Diseases Society of the Republic of China (IDSROC) | Cotrimoxazole | |||||||
Fluoroquinolon | ||||||||
Tanzania (52) | 2013 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Kikuli et al. | Complicated cystitis | Ciprofloxacin | 500 mg BID | 7 days |
Acute bacterial prostatitis | Men < 35 years or high-risk STI | |||||||
Ministry of Health | Cefixim | 400 mg OD | Single dose | |||||
then | ||||||||
Doxycyclin | 100 mg BID | 7 days | ||||||
Men > 35 years | ||||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Tonga (58) | 2007 | World Health Organization (WHO) | Pluriprofessional GP (No) | Siale ‘Akau’ ola et al. | Cystitis | First line | ||
Cefalexin | 500 mg BD | 14 days | ||||||
Ministry of Health | Nitrofurantoin | 50 mg QID | ||||||
Co-amoxiclav | 500/125 mg BD | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Pyelonephritis | First line | |||||||
Cefalexin | 500 mg QID | 14 days | ||||||
Co-amoxiclav | 500/125 mg TID | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
United Kingdom (23,44,45) | 2018 | National Institute for Health and Clinical Excellence | Pluriprofessional GP (Yes) | National Institute for Health Excellence (NICE) | Lower urinary tract infection/cystitis | Trimethoprim | 200 mg BD | 7 days |
Nitrofurantoin | 100 mg BD | 7 days | ||||||
Pyelonephritis | First choice | |||||||
Cefalexin | 500 mg BD or TID | 7–10 days | ||||||
Co-amoxiclav | 500/125 mg TID | 7–10 days | ||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Alternative first choice (IV) | ||||||||
Co-amoxiclav | 1.2 g TID | Oral relay as soon as possible after 48 hours | ||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 1–2 OD | |||||||
Ciprofloxacin | 400 mg BID TID | |||||||
Prostatitis | First choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
Alternative first choice | ||||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Second choice (after discussion with specialist) | ||||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
First choice IV if oral impossible | ||||||||
Ciprofloxacin | 400 mg BID TID | Orally after 48 hours, mini 14 days | ||||||
Levofloxacin | 500 mg OD | |||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 2 g OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cotrimoxazole | 800/160 mg BD | |||||||
Trimethoprim | N/A | |||||||
United States (54,55) | 2016 | MEDLINE | General Practice GP (Yes) | Timothy J.Coker et al. | Prostatitis | Men < 35 years OR high STI risk | ||
Ceftriaxon | 250 mg OD | Single dose | ||||||
American Academy of Family Physicians (AAFP) | or | |||||||
Cefixim | 400 mg OD | Single dose | ||||||
then | ||||||||
Doxycyclin | 100 mg BD | 10 days | ||||||
Men > 35 years AND low STI risk | ||||||||
Ciprofloxacin | 500 mg BD | 10–14 days | ||||||
Levofloxacin | 500–750 mg OD | |||||||
Alternative | ||||||||
Cotrimoxazole | 160/800 mg BID | 10–14 days | ||||||
2021 | Guideline Central, American Medical Association | Pluriprofessional GP (Yes) | C. Bettcher et al. | Complicated Cystitis | Nitrofurantoin | 100 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
University of Michigan Health System | Cefalexin | 500 mg BD | ||||||
Fosfomycin | 3 g every 48h | 3 doses | ||||||
Pyelonephritis | Ceftriaxon | 1 g | Single dose | |||||
followed by first line | ||||||||
Cotrimoxazole | 160/800 mg BD | 7–14 days | ||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 5 days | ||||||
Levofloxacin | 750 mg OD | |||||||
Third line | ||||||||
Co-amoxiclav | 875/125 mg BD | 10–14 days | ||||||
Prostatitis | Levofloxacin | 750 mg OD | 14 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | |||||||
Zimbabwe (53) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | Basopo Victor et al. | Cystitis | Norfloxacin | 400 mg BD | 3 days |
Ministry of Health | Pyelonephritis | Norfloxacin | 400 mg BD | 14 days |
Country . | Year of publication . | Databases . | Specialty . | Authors/society . | Classification . | Antibiotherapy . | Dosage . | Duration . |
---|---|---|---|---|---|---|---|---|
GP coauthors (yes/no) . | ||||||||
Argentina (56) | 2018 | MEDLINE | Pluriprofessional GP (No) | Corina Nemirovsky et al. | Cystitis | Nitrofurantoin | 100 mg QID | 7 days |
Cefalexin | 500 mg TID | |||||||
Alternative | ||||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Argentine Society of Infectious Diseases (ASID) | Pyelonephritis | Ceftriaxon | 1 g OD | 10 days | ||||
Cefixim | 400 mg OD | |||||||
Ciprofloxacin | 500 mg BD | 7 days | ||||||
Acute bacterial prostatitis | Ceftriaxon | 1–2 g OD | 2–4 weeks | |||||
Asia (49) | 2021 | MEDLINE | Urology GP (No) | Matsumoto et al. | Acute bacterial prostatitis | Probabilist | ||
Fluoroquinolon | N/A | 10–28 days | ||||||
Asian Association of Urinary Tract Infection and Sexually Transmitted Infection (AAUS) | After antibiogram: first choice | |||||||
Fluoroquinolon | N/A | 10–28 days | ||||||
After antibiogram: second choice if R-FQ | ||||||||
3rd CEP | N/A | 14–28 days | ||||||
Co-amoxiclav | N/A | |||||||
Cotrimoxazole | N/A | |||||||
Brazil (57) | 2005 | MEDLINE | Pluriprofessional GP (No) | Hélio Vasconcellos Lopes et al. | Cystitis | N/A | N/A | N/A |
Brazilian Society of Infectiology (SBI); Brazilian Society of Urology (SBU) | Pyelonephritis | N/A | N/A | N/A | ||||
Canada (Quebec) (60) | 2017 | National Institute for Health Excellence (INESS) | Pluriprofessional GP (Yes) | Fatiha Karam et al. | Complicated or at risk urinary tract infection | First choice | ||
Ciprofoloxacin | 500 mg BD | 10–14 days | ||||||
National Institute for Health Excellence (INESS) | Ciprofloxacin XL | 1000 mg OD | ||||||
Levofloxacin | 500 mg OD | |||||||
after obtaining the antibiogram only | ||||||||
Cotrimoxazole | 160/800 mg BD | Cystitis: 7–10 days | ||||||
Pyelonephritis: 10–14 days | ||||||||
Co-amoxiclav | 875–125 mg BD | 10–14 days | ||||||
Cefadroxil | 500 mg BID | |||||||
Cefalexin | 500 mg QID | |||||||
Cefixim | 400 mg OD | |||||||
Croatia (30,31) | 2004 | MEDLINE | Pluriprofessional GP (Yes) | Visnja Skerk et al. | Cystitis | 2nd CEP | N/A | 7 days |
Co-amoxiclav | ||||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Ciprofloxacin | |||||||
Nitrofurantoin | ||||||||
Cotrimoxazole | ||||||||
Pyelonephritis | N/A | N/A | N/A | |||||
Prostatitis | 2nd CEP | N/A | N/A | |||||
3rd CEP | N/A | N/A | ||||||
Co-amoxiclav | N/A | 4–6 weeks | ||||||
2004, updated in 2009 | MEDLINE | Pluriprofessional GP (Yes) | Visnja skerk et al. | Acute UTI and systemic symptoms | First choice | |||
Ciprofloxacin | 500 mg BD | 2 weeks | ||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Alternative choice | |||||||
Co-amoxiclav | 1 g BD | 2 weeks | ||||||
Cefuroxim-axétil | 500 mg BD | |||||||
Ceftibuten | 400 mg OD | |||||||
Cefixim | 400 mg OD | |||||||
Denmark (32) | 2020 | Common public health portal (Sundhed.dk) | Pluriprofessional GP (Yes) | Ulrich Stab Jensen et al. | Complicated urinary tract infection | Pivmecillinam | 400 mg TID | 5 days |
Nitrofurantoin | 100 mg BD | 5 days | ||||||
Sundhed | Pyelonephritis | Pivmecillinam | 400 mg TID | 10–14 days | ||||
Nitrofurantoin | 500 mg BD | 7 days | ||||||
Ethiopia (50) | 2010 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Eyasu Makonnen et al. | Male urinary tract infection | First choice | ||
Cotrimoxazole | 800/160 mg BD | 10–14 days | ||||||
Ministry of Health | Second choice | |||||||
Norfloxacin | 400 mg BD | 10–14 days | ||||||
Amoxicillin | 250–500 mg TID | |||||||
Europe (33,62) | 2001 | MEDLINE | Urology GP (No) | Kurt G. Naber et al. | Prostatitis | Fluoroquinolones | N/A | 14 days |
European Association of Urology (EAU) | 2nd CEP | N/A | ||||||
2001, updated in 2021 | Uroweb | Urology GP (No) | G. Bonkat et al. | Cystitis | Cotrimoxazole | 800/160 mg BD | 7 days | |
Restricted to men, fluoroquinolones can also be prescribed in accordance with local susceptibility testing | ||||||||
European Association of Urology (EAU) | Complicated UTIs | Ciprofloxacin | 500–750 mg | 14 days | ||||
3rd CEP | N/A | |||||||
Acute Bacterial Prostatitis | Same lines of complicated UTIs | |||||||
Finland (34,61) | 2011 | MEDLINE | Pluriprofessional GP (Yes) | R. De Rosa et al. | Cystitis | Trimethoprim | 160 mg BD or 300 m OD | 7–14 days |
Fluoroquinolones | N/A | |||||||
Finnish Medical Society Duodecim (DUODECIM) | Pyelonephritis | Fluoroquinolones | N/A | 14 days | ||||
Prostatitis | Fluoroquinolones | N/A | 4 weeks | |||||
2011, updated in 2021 | Finnish Medical Society DUODECIM* | Pluriprofessional GP (Yes) | Finnish Medical Society Duodecim (DUODECIM) | Cystitis | Trimethoprim | 160 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
Nitrofurantoin | 75 mg BD | |||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Pyelonephritis | Ciprofloxacin | 500 mg BD | 5–7 days | |||||
Levofloxacin | 250–500 mg OD | |||||||
Cefuroxim | 750–1500 mg TID | 10–14 days | ||||||
Cotrimoxazole | 160/800 mg x 2/d | 10 days | ||||||
Acute bacterial prostatitis | Cotrimoxazole | 160/800 mg OD | 4–6 weeks | |||||
Ciprofloxacin | N/A | |||||||
Norfloxacin | N/A | |||||||
France (22,63) | 2008 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Prostatitis | Ciprofloxacin | 500–750 mg BD | 15–21 days |
Levofloxacin | 500 mg OD | |||||||
French Infectious Diseases Society (SPILF) | Ofloxacin | 200 mg × 2–3/d | ||||||
2008, updated in 2018 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Male urinary tract infection | After obtaining the antibiogram only | |||
Pauci symptomatic (no fever) | First choice | |||||||
French Infectious Diseases Society (SPILF) | Ciprofloxacin | 500 mg BD | 14 days | |||||
Levofloxacin | 500 mg OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Second choice | ||||||||
Cotrimoxazole | 800/160 mg BD | 14 days | ||||||
Third choice | ||||||||
Cefotaxim | 1 g TID | 14 days | ||||||
Ceftriaxon | 1 g OD | |||||||
Male urinary tract infection | Same lines as male UTI pauci symptomatic in probabilistic | |||||||
symptomatic (fever) | ||||||||
Germany (35,36) | 2011, updated in 2017 | MEDLINE | Pluriprofessional GP (Yes) | F.M.E. Wagenlehner et al. (2011) | Cystitis (Healthy young men) | First choice | ||
Kranz et al. (2017) | Ciprofloxacin RT | 500 mg OD | 3 days | |||||
Ciprofloxacin | 250 mg BD | |||||||
German Association of Scientific Medical Societies (AWMF) | Levofloxacin | 250 mg OD | ||||||
Norfloxacin | 400 mg BD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cefpodoxim-proxetil | 100 mg BD | |||||||
According to local resistance rate | ||||||||
Cotrimoxazole | 160/800mg BD | 3 days | ||||||
Trimethoprim | 200 BD | 5 days | ||||||
Pyelonephritis | First choice | |||||||
Ciprofloxacin | 1000 mg OD | 7–10 days | ||||||
500–750 mg BD | ||||||||
Levofloxacin | 500 mg OD | |||||||
750 mg OD | 5 jours | |||||||
Second choice | ||||||||
Cefpodoxim-proxetil | 200 mg BD | 10 jours | ||||||
Ceftibuten | 400 mg OD | |||||||
After antibiogram | ||||||||
Cotrimoxazole | 160/800 mg BID | 14 jours | ||||||
Co-amoxiclav | 875/125 mg BID | |||||||
500/125 mg BID | ||||||||
Japan (46,83,84) | 2011, updated in 2015 and 2016 | MEDLINE | Pluriprofessional GP (No) | Yasuda et al. (2011/2016) | Complicated cystitis | First choice | ||
Yamamoto et al. (2015) | Levofloxacin | 500 mg OD | 7–14 days | |||||
Ciprofloxacin | 200 mg BID TID | |||||||
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy (JAID/JSC) | Temafloxacin | 150 mg BID | ||||||
Sitafloxacin | 100 mg OD | |||||||
Co-amoxiclav | 250 mg TID | |||||||
Sultamicillin | 375 mg TID | |||||||
Alternative | ||||||||
Cefdinir | 100 mg TID | 7–14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 mg TID | |||||||
Complicated pyelonephritis | First choice | |||||||
Levofloxacin | 500 mg OD | 7–14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Cefditoren pivoxil | 200 mg TID | 14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 TID | |||||||
Acute bacterial prostatitis | First choice | |||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Sultamicillin | 375 mg TID | 14–28 days | ||||||
Cotrimoxazole | 160/800 mg BID | 14 days | ||||||
Norway (37,38) | 2019 | Antibiotics Centre for Primary Medicine | General Practice GP (Yes) | Anders Baerheim et al. | Complicated cystitis (no fever) | Nitrofurantoin | 50 mg TID | 5–7 days |
Pivmecillinam | 200–400 mg TID | |||||||
Primary Care Antibiotic Centre | Trimethoprim | 160 mg BD | ||||||
Complicated cystitis (fever) | Cotrimoxazole | 160/800 mg × 2 BD | 5–7 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Sigurd Haugan Danielsen et al. | Prostatitis | First choice | ||||||
Cotrimoxazole | 160/800 mg × 2 BD | 14 days | ||||||
Primary Care Antibiotic Centre | Second choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
2021 | General Directorate of Health | Pluriprofessional GP (Yes) | Bjorn Waagsbo et al. | Complicated cystitis | Pivmecillinam | 200 mg TID | 7 days | |
Nitrofurantoin | 50 mg TID | |||||||
Norwegian Directorate of Health | Trimethoprim | 160 mg BD | ||||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Prostatitis | Ciprofloxacin | 500 mg BD | 14 days | |||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Cefotaxim | 1 g TID | |||||||
If atypical germs | ||||||||
Azithromycin | 1 g OD | 14 days | ||||||
Doxycycline | 100 mg OD | |||||||
Netherlands (39,40) | 2006 | MEDLINE | General Practice GP (Yes) | B. van Pinxteren et al. | Complicated urinary tract infection | First line | ||
Nitrofurantoin | N/A | 7 days | ||||||
College of General Practitioners (NHG) | Second line | |||||||
Trimethoprim | N/A | 7 days | ||||||
2013 | Dutch Working Party on Antibiotic Policy (SWAB) | Pluriprofessional GP (Yes) | Geerlings et al. | Cystitis (young men) | Cf. recommendations of College of General Practitioners (NHG) | |||
Urinary tract infection with systemic symptoms (pyelonephritis and acute prostatitis) | Ciprofloxacin | 500 mg BID | 14 days | |||||
Dutch Working Party on Antibiotic Policy (SWAB) | Cotrimoxazole | N/A | ||||||
2020 | College of General Practitioners (NHG) | Pluriprofessional GP (Yes) | M. Bouma et al. | Cystitis | First choice | |||
Nitrofurantoin | 100 mg BID | 7 days | ||||||
College of General Practitioners (NHG) | 50 mg QID | |||||||
Second choice | ||||||||
Trimethoprim | 300 mg OD | 7 days | ||||||
UTI with signs of tissue invasion | First choice | |||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Second choice | ||||||||
Co-amoxiclav | 500/125 mg TID | 14 days | ||||||
Third choice | ||||||||
Cotrimoxazole | 160/800 BID | 14 days | ||||||
Scotland (59) | 2012 | Scottish Intercollegiate | Pluriprofessional GP (No | Scottish Intercollegiate | Lower urinary tract infection | Trimethoprim | N/A | 7 days |
Guidelines Network (SIGN) | ) | Guidelines Network (SIGN) | Nitrofurantoin | N/A | ||||
Prostatitis | Quinolone | N/A | 4 weeks | |||||
South Africa (51) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | T.D. Mseleku et al. | Acute bacterial prostatitis | Men < 35 years old | ||
Ciprofloxacin | 500 mg | Single dose | ||||||
Ministry of Health | Followed by | |||||||
Doxycyclin | 100 mg BD | 7 days | ||||||
Men > 35 years old | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
South Korea (47) | 2018 | MEDLINE | Pluriprofessional GP (No) | Cheol-In Kang et al. | Pyelonephritis | Ciprofloxacin | 500 mg BD | 7 days |
Levofloxacin | 750 mg OD | 5 days | ||||||
Korean Society of Infectious Diseases (KSID) | Ceftibuten | 400 mg OD | 10 days | |||||
Cefpodoxim | 200 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
Prostatitis | 3rd CEP | N/A | 2–4 weeks | |||||
Co-amoxiclav | ||||||||
Spain (41) | 2017 | MEDLINE | Pluriprofessional GP (No) | Marina de Cueto et al. | Uncomplicated cystitis | N/A | N/A | 7 days minimum |
Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) | ||||||||
Sweden (42) | Public Health Agency | Pluriprofessional GP (Yes | Tegnell et al. | Cystitis | Ciprofloxacin | N/A | 2 weeks | |
) | Nitrofurantoin | 7 days | ||||||
Public Health Agency | Pivmecillinam | |||||||
Pyelonephritis | Ciprofloxacin | N/A | 2 weeks | |||||
Trimethoprim | N/A | |||||||
Switzerland (43) | 2014 | Swiss Society of Infectious Diseases | Pluriprofessional GP (No) | Barbara Hasse et al. | Cystitis | Fluoroquinolon | N/A | 7–10 days |
Cotrimoxazole | 7–10 days | |||||||
Swiss Society of Infectious Diseases | Pyelonephritis | Fluoroquinolone | N/A | 14 days | ||||
Cotrimoxazole | ||||||||
Prostatitis | Fluoroquinolon | N/A | 14–21 days | |||||
Cotrimoxazole | ||||||||
Taiwan (48) | 2000 | MEDLINE | Infectiology GP (No) | Feng-Yee Chang et al. | Prostatitis | Amoxicillin | N/A | N/A |
3rd CEP | ||||||||
Infectious Diseases Society of the Republic of China (IDSROC) | Cotrimoxazole | |||||||
Fluoroquinolon | ||||||||
Tanzania (52) | 2013 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Kikuli et al. | Complicated cystitis | Ciprofloxacin | 500 mg BID | 7 days |
Acute bacterial prostatitis | Men < 35 years or high-risk STI | |||||||
Ministry of Health | Cefixim | 400 mg OD | Single dose | |||||
then | ||||||||
Doxycyclin | 100 mg BID | 7 days | ||||||
Men > 35 years | ||||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Tonga (58) | 2007 | World Health Organization (WHO) | Pluriprofessional GP (No) | Siale ‘Akau’ ola et al. | Cystitis | First line | ||
Cefalexin | 500 mg BD | 14 days | ||||||
Ministry of Health | Nitrofurantoin | 50 mg QID | ||||||
Co-amoxiclav | 500/125 mg BD | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Pyelonephritis | First line | |||||||
Cefalexin | 500 mg QID | 14 days | ||||||
Co-amoxiclav | 500/125 mg TID | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
United Kingdom (23,44,45) | 2018 | National Institute for Health and Clinical Excellence | Pluriprofessional GP (Yes) | National Institute for Health Excellence (NICE) | Lower urinary tract infection/cystitis | Trimethoprim | 200 mg BD | 7 days |
Nitrofurantoin | 100 mg BD | 7 days | ||||||
Pyelonephritis | First choice | |||||||
Cefalexin | 500 mg BD or TID | 7–10 days | ||||||
Co-amoxiclav | 500/125 mg TID | 7–10 days | ||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Alternative first choice (IV) | ||||||||
Co-amoxiclav | 1.2 g TID | Oral relay as soon as possible after 48 hours | ||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 1–2 OD | |||||||
Ciprofloxacin | 400 mg BID TID | |||||||
Prostatitis | First choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
Alternative first choice | ||||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Second choice (after discussion with specialist) | ||||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
First choice IV if oral impossible | ||||||||
Ciprofloxacin | 400 mg BID TID | Orally after 48 hours, mini 14 days | ||||||
Levofloxacin | 500 mg OD | |||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 2 g OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cotrimoxazole | 800/160 mg BD | |||||||
Trimethoprim | N/A | |||||||
United States (54,55) | 2016 | MEDLINE | General Practice GP (Yes) | Timothy J.Coker et al. | Prostatitis | Men < 35 years OR high STI risk | ||
Ceftriaxon | 250 mg OD | Single dose | ||||||
American Academy of Family Physicians (AAFP) | or | |||||||
Cefixim | 400 mg OD | Single dose | ||||||
then | ||||||||
Doxycyclin | 100 mg BD | 10 days | ||||||
Men > 35 years AND low STI risk | ||||||||
Ciprofloxacin | 500 mg BD | 10–14 days | ||||||
Levofloxacin | 500–750 mg OD | |||||||
Alternative | ||||||||
Cotrimoxazole | 160/800 mg BID | 10–14 days | ||||||
2021 | Guideline Central, American Medical Association | Pluriprofessional GP (Yes) | C. Bettcher et al. | Complicated Cystitis | Nitrofurantoin | 100 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
University of Michigan Health System | Cefalexin | 500 mg BD | ||||||
Fosfomycin | 3 g every 48h | 3 doses | ||||||
Pyelonephritis | Ceftriaxon | 1 g | Single dose | |||||
followed by first line | ||||||||
Cotrimoxazole | 160/800 mg BD | 7–14 days | ||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 5 days | ||||||
Levofloxacin | 750 mg OD | |||||||
Third line | ||||||||
Co-amoxiclav | 875/125 mg BD | 10–14 days | ||||||
Prostatitis | Levofloxacin | 750 mg OD | 14 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | |||||||
Zimbabwe (53) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | Basopo Victor et al. | Cystitis | Norfloxacin | 400 mg BD | 3 days |
Ministry of Health | Pyelonephritis | Norfloxacin | 400 mg BD | 14 days |
N/A, not available, 2nd CEP, 2nd-generation cephalosporin, 3rd CEP, 3rd-generation cephalosporin, STI, sexually transmitted infection, OD, once daily, BD, twice daily, TID, thrice daily; QID, 4 times daily. All prescribed antibiotics are oral except for 3rd CEP (ceftriaxon, ceftazidim, cefotaxim) and 4th CEP (cefepim) which are either intravenous (IV).
*Translation from EBMFrance.net.
Country . | Year of publication . | Databases . | Specialty . | Authors/society . | Classification . | Antibiotherapy . | Dosage . | Duration . |
---|---|---|---|---|---|---|---|---|
GP coauthors (yes/no) . | ||||||||
Argentina (56) | 2018 | MEDLINE | Pluriprofessional GP (No) | Corina Nemirovsky et al. | Cystitis | Nitrofurantoin | 100 mg QID | 7 days |
Cefalexin | 500 mg TID | |||||||
Alternative | ||||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Argentine Society of Infectious Diseases (ASID) | Pyelonephritis | Ceftriaxon | 1 g OD | 10 days | ||||
Cefixim | 400 mg OD | |||||||
Ciprofloxacin | 500 mg BD | 7 days | ||||||
Acute bacterial prostatitis | Ceftriaxon | 1–2 g OD | 2–4 weeks | |||||
Asia (49) | 2021 | MEDLINE | Urology GP (No) | Matsumoto et al. | Acute bacterial prostatitis | Probabilist | ||
Fluoroquinolon | N/A | 10–28 days | ||||||
Asian Association of Urinary Tract Infection and Sexually Transmitted Infection (AAUS) | After antibiogram: first choice | |||||||
Fluoroquinolon | N/A | 10–28 days | ||||||
After antibiogram: second choice if R-FQ | ||||||||
3rd CEP | N/A | 14–28 days | ||||||
Co-amoxiclav | N/A | |||||||
Cotrimoxazole | N/A | |||||||
Brazil (57) | 2005 | MEDLINE | Pluriprofessional GP (No) | Hélio Vasconcellos Lopes et al. | Cystitis | N/A | N/A | N/A |
Brazilian Society of Infectiology (SBI); Brazilian Society of Urology (SBU) | Pyelonephritis | N/A | N/A | N/A | ||||
Canada (Quebec) (60) | 2017 | National Institute for Health Excellence (INESS) | Pluriprofessional GP (Yes) | Fatiha Karam et al. | Complicated or at risk urinary tract infection | First choice | ||
Ciprofoloxacin | 500 mg BD | 10–14 days | ||||||
National Institute for Health Excellence (INESS) | Ciprofloxacin XL | 1000 mg OD | ||||||
Levofloxacin | 500 mg OD | |||||||
after obtaining the antibiogram only | ||||||||
Cotrimoxazole | 160/800 mg BD | Cystitis: 7–10 days | ||||||
Pyelonephritis: 10–14 days | ||||||||
Co-amoxiclav | 875–125 mg BD | 10–14 days | ||||||
Cefadroxil | 500 mg BID | |||||||
Cefalexin | 500 mg QID | |||||||
Cefixim | 400 mg OD | |||||||
Croatia (30,31) | 2004 | MEDLINE | Pluriprofessional GP (Yes) | Visnja Skerk et al. | Cystitis | 2nd CEP | N/A | 7 days |
Co-amoxiclav | ||||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Ciprofloxacin | |||||||
Nitrofurantoin | ||||||||
Cotrimoxazole | ||||||||
Pyelonephritis | N/A | N/A | N/A | |||||
Prostatitis | 2nd CEP | N/A | N/A | |||||
3rd CEP | N/A | N/A | ||||||
Co-amoxiclav | N/A | 4–6 weeks | ||||||
2004, updated in 2009 | MEDLINE | Pluriprofessional GP (Yes) | Visnja skerk et al. | Acute UTI and systemic symptoms | First choice | |||
Ciprofloxacin | 500 mg BD | 2 weeks | ||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Alternative choice | |||||||
Co-amoxiclav | 1 g BD | 2 weeks | ||||||
Cefuroxim-axétil | 500 mg BD | |||||||
Ceftibuten | 400 mg OD | |||||||
Cefixim | 400 mg OD | |||||||
Denmark (32) | 2020 | Common public health portal (Sundhed.dk) | Pluriprofessional GP (Yes) | Ulrich Stab Jensen et al. | Complicated urinary tract infection | Pivmecillinam | 400 mg TID | 5 days |
Nitrofurantoin | 100 mg BD | 5 days | ||||||
Sundhed | Pyelonephritis | Pivmecillinam | 400 mg TID | 10–14 days | ||||
Nitrofurantoin | 500 mg BD | 7 days | ||||||
Ethiopia (50) | 2010 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Eyasu Makonnen et al. | Male urinary tract infection | First choice | ||
Cotrimoxazole | 800/160 mg BD | 10–14 days | ||||||
Ministry of Health | Second choice | |||||||
Norfloxacin | 400 mg BD | 10–14 days | ||||||
Amoxicillin | 250–500 mg TID | |||||||
Europe (33,62) | 2001 | MEDLINE | Urology GP (No) | Kurt G. Naber et al. | Prostatitis | Fluoroquinolones | N/A | 14 days |
European Association of Urology (EAU) | 2nd CEP | N/A | ||||||
2001, updated in 2021 | Uroweb | Urology GP (No) | G. Bonkat et al. | Cystitis | Cotrimoxazole | 800/160 mg BD | 7 days | |
Restricted to men, fluoroquinolones can also be prescribed in accordance with local susceptibility testing | ||||||||
European Association of Urology (EAU) | Complicated UTIs | Ciprofloxacin | 500–750 mg | 14 days | ||||
3rd CEP | N/A | |||||||
Acute Bacterial Prostatitis | Same lines of complicated UTIs | |||||||
Finland (34,61) | 2011 | MEDLINE | Pluriprofessional GP (Yes) | R. De Rosa et al. | Cystitis | Trimethoprim | 160 mg BD or 300 m OD | 7–14 days |
Fluoroquinolones | N/A | |||||||
Finnish Medical Society Duodecim (DUODECIM) | Pyelonephritis | Fluoroquinolones | N/A | 14 days | ||||
Prostatitis | Fluoroquinolones | N/A | 4 weeks | |||||
2011, updated in 2021 | Finnish Medical Society DUODECIM* | Pluriprofessional GP (Yes) | Finnish Medical Society Duodecim (DUODECIM) | Cystitis | Trimethoprim | 160 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
Nitrofurantoin | 75 mg BD | |||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Pyelonephritis | Ciprofloxacin | 500 mg BD | 5–7 days | |||||
Levofloxacin | 250–500 mg OD | |||||||
Cefuroxim | 750–1500 mg TID | 10–14 days | ||||||
Cotrimoxazole | 160/800 mg x 2/d | 10 days | ||||||
Acute bacterial prostatitis | Cotrimoxazole | 160/800 mg OD | 4–6 weeks | |||||
Ciprofloxacin | N/A | |||||||
Norfloxacin | N/A | |||||||
France (22,63) | 2008 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Prostatitis | Ciprofloxacin | 500–750 mg BD | 15–21 days |
Levofloxacin | 500 mg OD | |||||||
French Infectious Diseases Society (SPILF) | Ofloxacin | 200 mg × 2–3/d | ||||||
2008, updated in 2018 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Male urinary tract infection | After obtaining the antibiogram only | |||
Pauci symptomatic (no fever) | First choice | |||||||
French Infectious Diseases Society (SPILF) | Ciprofloxacin | 500 mg BD | 14 days | |||||
Levofloxacin | 500 mg OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Second choice | ||||||||
Cotrimoxazole | 800/160 mg BD | 14 days | ||||||
Third choice | ||||||||
Cefotaxim | 1 g TID | 14 days | ||||||
Ceftriaxon | 1 g OD | |||||||
Male urinary tract infection | Same lines as male UTI pauci symptomatic in probabilistic | |||||||
symptomatic (fever) | ||||||||
Germany (35,36) | 2011, updated in 2017 | MEDLINE | Pluriprofessional GP (Yes) | F.M.E. Wagenlehner et al. (2011) | Cystitis (Healthy young men) | First choice | ||
Kranz et al. (2017) | Ciprofloxacin RT | 500 mg OD | 3 days | |||||
Ciprofloxacin | 250 mg BD | |||||||
German Association of Scientific Medical Societies (AWMF) | Levofloxacin | 250 mg OD | ||||||
Norfloxacin | 400 mg BD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cefpodoxim-proxetil | 100 mg BD | |||||||
According to local resistance rate | ||||||||
Cotrimoxazole | 160/800mg BD | 3 days | ||||||
Trimethoprim | 200 BD | 5 days | ||||||
Pyelonephritis | First choice | |||||||
Ciprofloxacin | 1000 mg OD | 7–10 days | ||||||
500–750 mg BD | ||||||||
Levofloxacin | 500 mg OD | |||||||
750 mg OD | 5 jours | |||||||
Second choice | ||||||||
Cefpodoxim-proxetil | 200 mg BD | 10 jours | ||||||
Ceftibuten | 400 mg OD | |||||||
After antibiogram | ||||||||
Cotrimoxazole | 160/800 mg BID | 14 jours | ||||||
Co-amoxiclav | 875/125 mg BID | |||||||
500/125 mg BID | ||||||||
Japan (46,83,84) | 2011, updated in 2015 and 2016 | MEDLINE | Pluriprofessional GP (No) | Yasuda et al. (2011/2016) | Complicated cystitis | First choice | ||
Yamamoto et al. (2015) | Levofloxacin | 500 mg OD | 7–14 days | |||||
Ciprofloxacin | 200 mg BID TID | |||||||
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy (JAID/JSC) | Temafloxacin | 150 mg BID | ||||||
Sitafloxacin | 100 mg OD | |||||||
Co-amoxiclav | 250 mg TID | |||||||
Sultamicillin | 375 mg TID | |||||||
Alternative | ||||||||
Cefdinir | 100 mg TID | 7–14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 mg TID | |||||||
Complicated pyelonephritis | First choice | |||||||
Levofloxacin | 500 mg OD | 7–14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Cefditoren pivoxil | 200 mg TID | 14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 TID | |||||||
Acute bacterial prostatitis | First choice | |||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Sultamicillin | 375 mg TID | 14–28 days | ||||||
Cotrimoxazole | 160/800 mg BID | 14 days | ||||||
Norway (37,38) | 2019 | Antibiotics Centre for Primary Medicine | General Practice GP (Yes) | Anders Baerheim et al. | Complicated cystitis (no fever) | Nitrofurantoin | 50 mg TID | 5–7 days |
Pivmecillinam | 200–400 mg TID | |||||||
Primary Care Antibiotic Centre | Trimethoprim | 160 mg BD | ||||||
Complicated cystitis (fever) | Cotrimoxazole | 160/800 mg × 2 BD | 5–7 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Sigurd Haugan Danielsen et al. | Prostatitis | First choice | ||||||
Cotrimoxazole | 160/800 mg × 2 BD | 14 days | ||||||
Primary Care Antibiotic Centre | Second choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
2021 | General Directorate of Health | Pluriprofessional GP (Yes) | Bjorn Waagsbo et al. | Complicated cystitis | Pivmecillinam | 200 mg TID | 7 days | |
Nitrofurantoin | 50 mg TID | |||||||
Norwegian Directorate of Health | Trimethoprim | 160 mg BD | ||||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Prostatitis | Ciprofloxacin | 500 mg BD | 14 days | |||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Cefotaxim | 1 g TID | |||||||
If atypical germs | ||||||||
Azithromycin | 1 g OD | 14 days | ||||||
Doxycycline | 100 mg OD | |||||||
Netherlands (39,40) | 2006 | MEDLINE | General Practice GP (Yes) | B. van Pinxteren et al. | Complicated urinary tract infection | First line | ||
Nitrofurantoin | N/A | 7 days | ||||||
College of General Practitioners (NHG) | Second line | |||||||
Trimethoprim | N/A | 7 days | ||||||
2013 | Dutch Working Party on Antibiotic Policy (SWAB) | Pluriprofessional GP (Yes) | Geerlings et al. | Cystitis (young men) | Cf. recommendations of College of General Practitioners (NHG) | |||
Urinary tract infection with systemic symptoms (pyelonephritis and acute prostatitis) | Ciprofloxacin | 500 mg BID | 14 days | |||||
Dutch Working Party on Antibiotic Policy (SWAB) | Cotrimoxazole | N/A | ||||||
2020 | College of General Practitioners (NHG) | Pluriprofessional GP (Yes) | M. Bouma et al. | Cystitis | First choice | |||
Nitrofurantoin | 100 mg BID | 7 days | ||||||
College of General Practitioners (NHG) | 50 mg QID | |||||||
Second choice | ||||||||
Trimethoprim | 300 mg OD | 7 days | ||||||
UTI with signs of tissue invasion | First choice | |||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Second choice | ||||||||
Co-amoxiclav | 500/125 mg TID | 14 days | ||||||
Third choice | ||||||||
Cotrimoxazole | 160/800 BID | 14 days | ||||||
Scotland (59) | 2012 | Scottish Intercollegiate | Pluriprofessional GP (No | Scottish Intercollegiate | Lower urinary tract infection | Trimethoprim | N/A | 7 days |
Guidelines Network (SIGN) | ) | Guidelines Network (SIGN) | Nitrofurantoin | N/A | ||||
Prostatitis | Quinolone | N/A | 4 weeks | |||||
South Africa (51) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | T.D. Mseleku et al. | Acute bacterial prostatitis | Men < 35 years old | ||
Ciprofloxacin | 500 mg | Single dose | ||||||
Ministry of Health | Followed by | |||||||
Doxycyclin | 100 mg BD | 7 days | ||||||
Men > 35 years old | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
South Korea (47) | 2018 | MEDLINE | Pluriprofessional GP (No) | Cheol-In Kang et al. | Pyelonephritis | Ciprofloxacin | 500 mg BD | 7 days |
Levofloxacin | 750 mg OD | 5 days | ||||||
Korean Society of Infectious Diseases (KSID) | Ceftibuten | 400 mg OD | 10 days | |||||
Cefpodoxim | 200 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
Prostatitis | 3rd CEP | N/A | 2–4 weeks | |||||
Co-amoxiclav | ||||||||
Spain (41) | 2017 | MEDLINE | Pluriprofessional GP (No) | Marina de Cueto et al. | Uncomplicated cystitis | N/A | N/A | 7 days minimum |
Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) | ||||||||
Sweden (42) | Public Health Agency | Pluriprofessional GP (Yes | Tegnell et al. | Cystitis | Ciprofloxacin | N/A | 2 weeks | |
) | Nitrofurantoin | 7 days | ||||||
Public Health Agency | Pivmecillinam | |||||||
Pyelonephritis | Ciprofloxacin | N/A | 2 weeks | |||||
Trimethoprim | N/A | |||||||
Switzerland (43) | 2014 | Swiss Society of Infectious Diseases | Pluriprofessional GP (No) | Barbara Hasse et al. | Cystitis | Fluoroquinolon | N/A | 7–10 days |
Cotrimoxazole | 7–10 days | |||||||
Swiss Society of Infectious Diseases | Pyelonephritis | Fluoroquinolone | N/A | 14 days | ||||
Cotrimoxazole | ||||||||
Prostatitis | Fluoroquinolon | N/A | 14–21 days | |||||
Cotrimoxazole | ||||||||
Taiwan (48) | 2000 | MEDLINE | Infectiology GP (No) | Feng-Yee Chang et al. | Prostatitis | Amoxicillin | N/A | N/A |
3rd CEP | ||||||||
Infectious Diseases Society of the Republic of China (IDSROC) | Cotrimoxazole | |||||||
Fluoroquinolon | ||||||||
Tanzania (52) | 2013 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Kikuli et al. | Complicated cystitis | Ciprofloxacin | 500 mg BID | 7 days |
Acute bacterial prostatitis | Men < 35 years or high-risk STI | |||||||
Ministry of Health | Cefixim | 400 mg OD | Single dose | |||||
then | ||||||||
Doxycyclin | 100 mg BID | 7 days | ||||||
Men > 35 years | ||||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Tonga (58) | 2007 | World Health Organization (WHO) | Pluriprofessional GP (No) | Siale ‘Akau’ ola et al. | Cystitis | First line | ||
Cefalexin | 500 mg BD | 14 days | ||||||
Ministry of Health | Nitrofurantoin | 50 mg QID | ||||||
Co-amoxiclav | 500/125 mg BD | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Pyelonephritis | First line | |||||||
Cefalexin | 500 mg QID | 14 days | ||||||
Co-amoxiclav | 500/125 mg TID | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
United Kingdom (23,44,45) | 2018 | National Institute for Health and Clinical Excellence | Pluriprofessional GP (Yes) | National Institute for Health Excellence (NICE) | Lower urinary tract infection/cystitis | Trimethoprim | 200 mg BD | 7 days |
Nitrofurantoin | 100 mg BD | 7 days | ||||||
Pyelonephritis | First choice | |||||||
Cefalexin | 500 mg BD or TID | 7–10 days | ||||||
Co-amoxiclav | 500/125 mg TID | 7–10 days | ||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Alternative first choice (IV) | ||||||||
Co-amoxiclav | 1.2 g TID | Oral relay as soon as possible after 48 hours | ||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 1–2 OD | |||||||
Ciprofloxacin | 400 mg BID TID | |||||||
Prostatitis | First choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
Alternative first choice | ||||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Second choice (after discussion with specialist) | ||||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
First choice IV if oral impossible | ||||||||
Ciprofloxacin | 400 mg BID TID | Orally after 48 hours, mini 14 days | ||||||
Levofloxacin | 500 mg OD | |||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 2 g OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cotrimoxazole | 800/160 mg BD | |||||||
Trimethoprim | N/A | |||||||
United States (54,55) | 2016 | MEDLINE | General Practice GP (Yes) | Timothy J.Coker et al. | Prostatitis | Men < 35 years OR high STI risk | ||
Ceftriaxon | 250 mg OD | Single dose | ||||||
American Academy of Family Physicians (AAFP) | or | |||||||
Cefixim | 400 mg OD | Single dose | ||||||
then | ||||||||
Doxycyclin | 100 mg BD | 10 days | ||||||
Men > 35 years AND low STI risk | ||||||||
Ciprofloxacin | 500 mg BD | 10–14 days | ||||||
Levofloxacin | 500–750 mg OD | |||||||
Alternative | ||||||||
Cotrimoxazole | 160/800 mg BID | 10–14 days | ||||||
2021 | Guideline Central, American Medical Association | Pluriprofessional GP (Yes) | C. Bettcher et al. | Complicated Cystitis | Nitrofurantoin | 100 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
University of Michigan Health System | Cefalexin | 500 mg BD | ||||||
Fosfomycin | 3 g every 48h | 3 doses | ||||||
Pyelonephritis | Ceftriaxon | 1 g | Single dose | |||||
followed by first line | ||||||||
Cotrimoxazole | 160/800 mg BD | 7–14 days | ||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 5 days | ||||||
Levofloxacin | 750 mg OD | |||||||
Third line | ||||||||
Co-amoxiclav | 875/125 mg BD | 10–14 days | ||||||
Prostatitis | Levofloxacin | 750 mg OD | 14 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | |||||||
Zimbabwe (53) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | Basopo Victor et al. | Cystitis | Norfloxacin | 400 mg BD | 3 days |
Ministry of Health | Pyelonephritis | Norfloxacin | 400 mg BD | 14 days |
Country . | Year of publication . | Databases . | Specialty . | Authors/society . | Classification . | Antibiotherapy . | Dosage . | Duration . |
---|---|---|---|---|---|---|---|---|
GP coauthors (yes/no) . | ||||||||
Argentina (56) | 2018 | MEDLINE | Pluriprofessional GP (No) | Corina Nemirovsky et al. | Cystitis | Nitrofurantoin | 100 mg QID | 7 days |
Cefalexin | 500 mg TID | |||||||
Alternative | ||||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Argentine Society of Infectious Diseases (ASID) | Pyelonephritis | Ceftriaxon | 1 g OD | 10 days | ||||
Cefixim | 400 mg OD | |||||||
Ciprofloxacin | 500 mg BD | 7 days | ||||||
Acute bacterial prostatitis | Ceftriaxon | 1–2 g OD | 2–4 weeks | |||||
Asia (49) | 2021 | MEDLINE | Urology GP (No) | Matsumoto et al. | Acute bacterial prostatitis | Probabilist | ||
Fluoroquinolon | N/A | 10–28 days | ||||||
Asian Association of Urinary Tract Infection and Sexually Transmitted Infection (AAUS) | After antibiogram: first choice | |||||||
Fluoroquinolon | N/A | 10–28 days | ||||||
After antibiogram: second choice if R-FQ | ||||||||
3rd CEP | N/A | 14–28 days | ||||||
Co-amoxiclav | N/A | |||||||
Cotrimoxazole | N/A | |||||||
Brazil (57) | 2005 | MEDLINE | Pluriprofessional GP (No) | Hélio Vasconcellos Lopes et al. | Cystitis | N/A | N/A | N/A |
Brazilian Society of Infectiology (SBI); Brazilian Society of Urology (SBU) | Pyelonephritis | N/A | N/A | N/A | ||||
Canada (Quebec) (60) | 2017 | National Institute for Health Excellence (INESS) | Pluriprofessional GP (Yes) | Fatiha Karam et al. | Complicated or at risk urinary tract infection | First choice | ||
Ciprofoloxacin | 500 mg BD | 10–14 days | ||||||
National Institute for Health Excellence (INESS) | Ciprofloxacin XL | 1000 mg OD | ||||||
Levofloxacin | 500 mg OD | |||||||
after obtaining the antibiogram only | ||||||||
Cotrimoxazole | 160/800 mg BD | Cystitis: 7–10 days | ||||||
Pyelonephritis: 10–14 days | ||||||||
Co-amoxiclav | 875–125 mg BD | 10–14 days | ||||||
Cefadroxil | 500 mg BID | |||||||
Cefalexin | 500 mg QID | |||||||
Cefixim | 400 mg OD | |||||||
Croatia (30,31) | 2004 | MEDLINE | Pluriprofessional GP (Yes) | Visnja Skerk et al. | Cystitis | 2nd CEP | N/A | 7 days |
Co-amoxiclav | ||||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Ciprofloxacin | |||||||
Nitrofurantoin | ||||||||
Cotrimoxazole | ||||||||
Pyelonephritis | N/A | N/A | N/A | |||||
Prostatitis | 2nd CEP | N/A | N/A | |||||
3rd CEP | N/A | N/A | ||||||
Co-amoxiclav | N/A | 4–6 weeks | ||||||
2004, updated in 2009 | MEDLINE | Pluriprofessional GP (Yes) | Visnja skerk et al. | Acute UTI and systemic symptoms | First choice | |||
Ciprofloxacin | 500 mg BD | 2 weeks | ||||||
Interdisciplinary Section for Antibiotic Resistance Control (ISKRA) | Alternative choice | |||||||
Co-amoxiclav | 1 g BD | 2 weeks | ||||||
Cefuroxim-axétil | 500 mg BD | |||||||
Ceftibuten | 400 mg OD | |||||||
Cefixim | 400 mg OD | |||||||
Denmark (32) | 2020 | Common public health portal (Sundhed.dk) | Pluriprofessional GP (Yes) | Ulrich Stab Jensen et al. | Complicated urinary tract infection | Pivmecillinam | 400 mg TID | 5 days |
Nitrofurantoin | 100 mg BD | 5 days | ||||||
Sundhed | Pyelonephritis | Pivmecillinam | 400 mg TID | 10–14 days | ||||
Nitrofurantoin | 500 mg BD | 7 days | ||||||
Ethiopia (50) | 2010 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Eyasu Makonnen et al. | Male urinary tract infection | First choice | ||
Cotrimoxazole | 800/160 mg BD | 10–14 days | ||||||
Ministry of Health | Second choice | |||||||
Norfloxacin | 400 mg BD | 10–14 days | ||||||
Amoxicillin | 250–500 mg TID | |||||||
Europe (33,62) | 2001 | MEDLINE | Urology GP (No) | Kurt G. Naber et al. | Prostatitis | Fluoroquinolones | N/A | 14 days |
European Association of Urology (EAU) | 2nd CEP | N/A | ||||||
2001, updated in 2021 | Uroweb | Urology GP (No) | G. Bonkat et al. | Cystitis | Cotrimoxazole | 800/160 mg BD | 7 days | |
Restricted to men, fluoroquinolones can also be prescribed in accordance with local susceptibility testing | ||||||||
European Association of Urology (EAU) | Complicated UTIs | Ciprofloxacin | 500–750 mg | 14 days | ||||
3rd CEP | N/A | |||||||
Acute Bacterial Prostatitis | Same lines of complicated UTIs | |||||||
Finland (34,61) | 2011 | MEDLINE | Pluriprofessional GP (Yes) | R. De Rosa et al. | Cystitis | Trimethoprim | 160 mg BD or 300 m OD | 7–14 days |
Fluoroquinolones | N/A | |||||||
Finnish Medical Society Duodecim (DUODECIM) | Pyelonephritis | Fluoroquinolones | N/A | 14 days | ||||
Prostatitis | Fluoroquinolones | N/A | 4 weeks | |||||
2011, updated in 2021 | Finnish Medical Society DUODECIM* | Pluriprofessional GP (Yes) | Finnish Medical Society Duodecim (DUODECIM) | Cystitis | Trimethoprim | 160 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
Nitrofurantoin | 75 mg BD | |||||||
Fosfomycin | 3 g OD | Single dose | ||||||
Pyelonephritis | Ciprofloxacin | 500 mg BD | 5–7 days | |||||
Levofloxacin | 250–500 mg OD | |||||||
Cefuroxim | 750–1500 mg TID | 10–14 days | ||||||
Cotrimoxazole | 160/800 mg x 2/d | 10 days | ||||||
Acute bacterial prostatitis | Cotrimoxazole | 160/800 mg OD | 4–6 weeks | |||||
Ciprofloxacin | N/A | |||||||
Norfloxacin | N/A | |||||||
France (22,63) | 2008 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Prostatitis | Ciprofloxacin | 500–750 mg BD | 15–21 days |
Levofloxacin | 500 mg OD | |||||||
French Infectious Diseases Society (SPILF) | Ofloxacin | 200 mg × 2–3/d | ||||||
2008, updated in 2018 | MEDLINE | Pluriprofessional GP (Yes) | F. Caron et al. | Male urinary tract infection | After obtaining the antibiogram only | |||
Pauci symptomatic (no fever) | First choice | |||||||
French Infectious Diseases Society (SPILF) | Ciprofloxacin | 500 mg BD | 14 days | |||||
Levofloxacin | 500 mg OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Second choice | ||||||||
Cotrimoxazole | 800/160 mg BD | 14 days | ||||||
Third choice | ||||||||
Cefotaxim | 1 g TID | 14 days | ||||||
Ceftriaxon | 1 g OD | |||||||
Male urinary tract infection | Same lines as male UTI pauci symptomatic in probabilistic | |||||||
symptomatic (fever) | ||||||||
Germany (35,36) | 2011, updated in 2017 | MEDLINE | Pluriprofessional GP (Yes) | F.M.E. Wagenlehner et al. (2011) | Cystitis (Healthy young men) | First choice | ||
Kranz et al. (2017) | Ciprofloxacin RT | 500 mg OD | 3 days | |||||
Ciprofloxacin | 250 mg BD | |||||||
German Association of Scientific Medical Societies (AWMF) | Levofloxacin | 250 mg OD | ||||||
Norfloxacin | 400 mg BD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cefpodoxim-proxetil | 100 mg BD | |||||||
According to local resistance rate | ||||||||
Cotrimoxazole | 160/800mg BD | 3 days | ||||||
Trimethoprim | 200 BD | 5 days | ||||||
Pyelonephritis | First choice | |||||||
Ciprofloxacin | 1000 mg OD | 7–10 days | ||||||
500–750 mg BD | ||||||||
Levofloxacin | 500 mg OD | |||||||
750 mg OD | 5 jours | |||||||
Second choice | ||||||||
Cefpodoxim-proxetil | 200 mg BD | 10 jours | ||||||
Ceftibuten | 400 mg OD | |||||||
After antibiogram | ||||||||
Cotrimoxazole | 160/800 mg BID | 14 jours | ||||||
Co-amoxiclav | 875/125 mg BID | |||||||
500/125 mg BID | ||||||||
Japan (46,83,84) | 2011, updated in 2015 and 2016 | MEDLINE | Pluriprofessional GP (No) | Yasuda et al. (2011/2016) | Complicated cystitis | First choice | ||
Yamamoto et al. (2015) | Levofloxacin | 500 mg OD | 7–14 days | |||||
Ciprofloxacin | 200 mg BID TID | |||||||
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy (JAID/JSC) | Temafloxacin | 150 mg BID | ||||||
Sitafloxacin | 100 mg OD | |||||||
Co-amoxiclav | 250 mg TID | |||||||
Sultamicillin | 375 mg TID | |||||||
Alternative | ||||||||
Cefdinir | 100 mg TID | 7–14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 mg TID | |||||||
Complicated pyelonephritis | First choice | |||||||
Levofloxacin | 500 mg OD | 7–14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Cefditoren pivoxil | 200 mg TID | 14 days | ||||||
Cefpodoxim | 200 mg BID | |||||||
Cefcapene-pivoxil | 100–150 TID | |||||||
Acute bacterial prostatitis | First choice | |||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Ciprofloxacin | 200 mg BID TID | |||||||
Temafloxacin | 150 mg BID | |||||||
Sitafloxacin | 100 mg OD | |||||||
Alternative | ||||||||
Sultamicillin | 375 mg TID | 14–28 days | ||||||
Cotrimoxazole | 160/800 mg BID | 14 days | ||||||
Norway (37,38) | 2019 | Antibiotics Centre for Primary Medicine | General Practice GP (Yes) | Anders Baerheim et al. | Complicated cystitis (no fever) | Nitrofurantoin | 50 mg TID | 5–7 days |
Pivmecillinam | 200–400 mg TID | |||||||
Primary Care Antibiotic Centre | Trimethoprim | 160 mg BD | ||||||
Complicated cystitis (fever) | Cotrimoxazole | 160/800 mg × 2 BD | 5–7 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Sigurd Haugan Danielsen et al. | Prostatitis | First choice | ||||||
Cotrimoxazole | 160/800 mg × 2 BD | 14 days | ||||||
Primary Care Antibiotic Centre | Second choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
2021 | General Directorate of Health | Pluriprofessional GP (Yes) | Bjorn Waagsbo et al. | Complicated cystitis | Pivmecillinam | 200 mg TID | 7 days | |
Nitrofurantoin | 50 mg TID | |||||||
Norwegian Directorate of Health | Trimethoprim | 160 mg BD | ||||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Prostatitis | Ciprofloxacin | 500 mg BD | 14 days | |||||
Cotrimoxazole | 160/800 mg x 2 BD | |||||||
Cefotaxim | 1 g TID | |||||||
If atypical germs | ||||||||
Azithromycin | 1 g OD | 14 days | ||||||
Doxycycline | 100 mg OD | |||||||
Netherlands (39,40) | 2006 | MEDLINE | General Practice GP (Yes) | B. van Pinxteren et al. | Complicated urinary tract infection | First line | ||
Nitrofurantoin | N/A | 7 days | ||||||
College of General Practitioners (NHG) | Second line | |||||||
Trimethoprim | N/A | 7 days | ||||||
2013 | Dutch Working Party on Antibiotic Policy (SWAB) | Pluriprofessional GP (Yes) | Geerlings et al. | Cystitis (young men) | Cf. recommendations of College of General Practitioners (NHG) | |||
Urinary tract infection with systemic symptoms (pyelonephritis and acute prostatitis) | Ciprofloxacin | 500 mg BID | 14 days | |||||
Dutch Working Party on Antibiotic Policy (SWAB) | Cotrimoxazole | N/A | ||||||
2020 | College of General Practitioners (NHG) | Pluriprofessional GP (Yes) | M. Bouma et al. | Cystitis | First choice | |||
Nitrofurantoin | 100 mg BID | 7 days | ||||||
College of General Practitioners (NHG) | 50 mg QID | |||||||
Second choice | ||||||||
Trimethoprim | 300 mg OD | 7 days | ||||||
UTI with signs of tissue invasion | First choice | |||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Second choice | ||||||||
Co-amoxiclav | 500/125 mg TID | 14 days | ||||||
Third choice | ||||||||
Cotrimoxazole | 160/800 BID | 14 days | ||||||
Scotland (59) | 2012 | Scottish Intercollegiate | Pluriprofessional GP (No | Scottish Intercollegiate | Lower urinary tract infection | Trimethoprim | N/A | 7 days |
Guidelines Network (SIGN) | ) | Guidelines Network (SIGN) | Nitrofurantoin | N/A | ||||
Prostatitis | Quinolone | N/A | 4 weeks | |||||
South Africa (51) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | T.D. Mseleku et al. | Acute bacterial prostatitis | Men < 35 years old | ||
Ciprofloxacin | 500 mg | Single dose | ||||||
Ministry of Health | Followed by | |||||||
Doxycyclin | 100 mg BD | 7 days | ||||||
Men > 35 years old | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
South Korea (47) | 2018 | MEDLINE | Pluriprofessional GP (No) | Cheol-In Kang et al. | Pyelonephritis | Ciprofloxacin | 500 mg BD | 7 days |
Levofloxacin | 750 mg OD | 5 days | ||||||
Korean Society of Infectious Diseases (KSID) | Ceftibuten | 400 mg OD | 10 days | |||||
Cefpodoxim | 200 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
Prostatitis | 3rd CEP | N/A | 2–4 weeks | |||||
Co-amoxiclav | ||||||||
Spain (41) | 2017 | MEDLINE | Pluriprofessional GP (No) | Marina de Cueto et al. | Uncomplicated cystitis | N/A | N/A | 7 days minimum |
Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) | ||||||||
Sweden (42) | Public Health Agency | Pluriprofessional GP (Yes | Tegnell et al. | Cystitis | Ciprofloxacin | N/A | 2 weeks | |
) | Nitrofurantoin | 7 days | ||||||
Public Health Agency | Pivmecillinam | |||||||
Pyelonephritis | Ciprofloxacin | N/A | 2 weeks | |||||
Trimethoprim | N/A | |||||||
Switzerland (43) | 2014 | Swiss Society of Infectious Diseases | Pluriprofessional GP (No) | Barbara Hasse et al. | Cystitis | Fluoroquinolon | N/A | 7–10 days |
Cotrimoxazole | 7–10 days | |||||||
Swiss Society of Infectious Diseases | Pyelonephritis | Fluoroquinolone | N/A | 14 days | ||||
Cotrimoxazole | ||||||||
Prostatitis | Fluoroquinolon | N/A | 14–21 days | |||||
Cotrimoxazole | ||||||||
Taiwan (48) | 2000 | MEDLINE | Infectiology GP (No) | Feng-Yee Chang et al. | Prostatitis | Amoxicillin | N/A | N/A |
3rd CEP | ||||||||
Infectious Diseases Society of the Republic of China (IDSROC) | Cotrimoxazole | |||||||
Fluoroquinolon | ||||||||
Tanzania (52) | 2013 | World Health Organization (WHO) | Pluriprofessional GP (Yes) | Kikuli et al. | Complicated cystitis | Ciprofloxacin | 500 mg BID | 7 days |
Acute bacterial prostatitis | Men < 35 years or high-risk STI | |||||||
Ministry of Health | Cefixim | 400 mg OD | Single dose | |||||
then | ||||||||
Doxycyclin | 100 mg BID | 7 days | ||||||
Men > 35 years | ||||||||
Ciprofloxacin | 500 mg BID | 14 days | ||||||
Tonga (58) | 2007 | World Health Organization (WHO) | Pluriprofessional GP (No) | Siale ‘Akau’ ola et al. | Cystitis | First line | ||
Cefalexin | 500 mg BD | 14 days | ||||||
Ministry of Health | Nitrofurantoin | 50 mg QID | ||||||
Co-amoxiclav | 500/125 mg BD | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Pyelonephritis | First line | |||||||
Cefalexin | 500 mg QID | 14 days | ||||||
Co-amoxiclav | 500/125 mg TID | |||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
United Kingdom (23,44,45) | 2018 | National Institute for Health and Clinical Excellence | Pluriprofessional GP (Yes) | National Institute for Health Excellence (NICE) | Lower urinary tract infection/cystitis | Trimethoprim | 200 mg BD | 7 days |
Nitrofurantoin | 100 mg BD | 7 days | ||||||
Pyelonephritis | First choice | |||||||
Cefalexin | 500 mg BD or TID | 7–10 days | ||||||
Co-amoxiclav | 500/125 mg TID | 7–10 days | ||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Alternative first choice (IV) | ||||||||
Co-amoxiclav | 1.2 g TID | Oral relay as soon as possible after 48 hours | ||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 1–2 OD | |||||||
Ciprofloxacin | 400 mg BID TID | |||||||
Prostatitis | First choice | |||||||
Ciprofloxacin | 500 mg BD | 14 days | ||||||
Ofloxacin | 200 mg BD | |||||||
Alternative first choice | ||||||||
Trimethoprim | 200 mg BD | 14 days | ||||||
Second choice (after discussion with specialist) | ||||||||
Levofloxacin | 500 mg OD | 14 days | ||||||
Cotrimoxazole | 160/800 mg BD | 14 days | ||||||
First choice IV if oral impossible | ||||||||
Ciprofloxacin | 400 mg BID TID | Orally after 48 hours, mini 14 days | ||||||
Levofloxacin | 500 mg OD | |||||||
Cefuroxim | 1.5 g TID QID | |||||||
Ceftriaxon | 2 g OD | |||||||
Ofloxacin | 200 mg BD | |||||||
Cotrimoxazole | 800/160 mg BD | |||||||
Trimethoprim | N/A | |||||||
United States (54,55) | 2016 | MEDLINE | General Practice GP (Yes) | Timothy J.Coker et al. | Prostatitis | Men < 35 years OR high STI risk | ||
Ceftriaxon | 250 mg OD | Single dose | ||||||
American Academy of Family Physicians (AAFP) | or | |||||||
Cefixim | 400 mg OD | Single dose | ||||||
then | ||||||||
Doxycyclin | 100 mg BD | 10 days | ||||||
Men > 35 years AND low STI risk | ||||||||
Ciprofloxacin | 500 mg BD | 10–14 days | ||||||
Levofloxacin | 500–750 mg OD | |||||||
Alternative | ||||||||
Cotrimoxazole | 160/800 mg BID | 10–14 days | ||||||
2021 | Guideline Central, American Medical Association | Pluriprofessional GP (Yes) | C. Bettcher et al. | Complicated Cystitis | Nitrofurantoin | 100 mg BD | 7 days | |
Cotrimoxazole | 160/800 mg BD | |||||||
University of Michigan Health System | Cefalexin | 500 mg BD | ||||||
Fosfomycin | 3 g every 48h | 3 doses | ||||||
Pyelonephritis | Ceftriaxon | 1 g | Single dose | |||||
followed by first line | ||||||||
Cotrimoxazole | 160/800 mg BD | 7–14 days | ||||||
Second line | ||||||||
Ciprofloxacin | 500 mg BD | 5 days | ||||||
Levofloxacin | 750 mg OD | |||||||
Third line | ||||||||
Co-amoxiclav | 875/125 mg BD | 10–14 days | ||||||
Prostatitis | Levofloxacin | 750 mg OD | 14 days | |||||
Ciprofloxacin | 500 mg BD | |||||||
Cotrimoxazole | 160/800 mg BD | |||||||
Zimbabwe (53) | 2006 | World Health Organization (WHO) | Pluriprofessional GP (No) | Basopo Victor et al. | Cystitis | Norfloxacin | 400 mg BD | 3 days |
Ministry of Health | Pyelonephritis | Norfloxacin | 400 mg BD | 14 days |
N/A, not available, 2nd CEP, 2nd-generation cephalosporin, 3rd CEP, 3rd-generation cephalosporin, STI, sexually transmitted infection, OD, once daily, BD, twice daily, TID, thrice daily; QID, 4 times daily. All prescribed antibiotics are oral except for 3rd CEP (ceftriaxon, ceftazidim, cefotaxim) and 4th CEP (cefepim) which are either intravenous (IV).
*Translation from EBMFrance.net.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.